AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25052387 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth group (TG) for patients with comorbidity
Number of subjects: 45
Study 25052387 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) for patients with comorbidity
Number of subjects: 45
Study 22782791 — intervention group
Group type: EXPERIMENTAL
Intervention: Duet (precoital use)
Number of subjects: 80
Study 22782791 — intervention group
Group type: EXPERIMENTAL
Intervention: Duet (daily use)
Number of subjects: 80
Study 22782791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both use-regimens
Number of subjects: 80
Study 22782791 — intervention group
Group type: COMPARATOR
Intervention: Duet and BufferGel (overall adherence)
Number of subjects: 80
Study 22782791 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm experience
Number of subjects: 80
Study 20593911 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg/HCTZ 12.5 mg
Number of subjects: 846
Study 20593911 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan medoxomil 40 mg
Number of subjects: 846
Study 20593911 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-titration from olmesartan medoxomil 40 mg to olmesartan medoxomil 40 mg/HCTZ 12.5 mg
Number of subjects: 846
Study 20593911 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-titration from olmesartan medoxomil 40 mg/HCTZ 12.5 mg to olmesartan medoxomil 40 mg/HCTZ 25 mg
Number of subjects: 846
Study 20593911 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of HCTZ 12.5 mg to olmesartan medoxomil 40 mg
Number of subjects: 846
Study 20593911 — intervention group
Group type: COMPARATOR
Intervention: Continuation on olmesartan medoxomil 40 mg
Number of subjects: 846
Study 18370581 — intervention group
Group type: EXPERIMENTAL
Intervention: CTS-targeted massage (TM)
Number of subjects: 27
Study 18370581 — intervention group
Group type: COMPARATOR
Intervention: General massage (GM)
Number of subjects: 27
Study 15747127 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical suture line related to midline (VLRM, n=16)
Number of subjects: 34
Study 15747127 — intervention group
Group type: COMPARATOR
Intervention: Vertical suture line unrelated to midline (VLUM, n=18)
Number of subjects: 34
Study 12209710 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative doxorubicin and cyclophosphamide (AC)
Number of subjects: 1234
Study 12209710 — intervention group
Group type: COMPARATOR
Intervention: Postoperative doxorubicin and cyclophosphamide (AC)
Number of subjects: 1234
Study 10331708 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral (cyclosporine)
Number of subjects: 227
Study 8923830 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I 100 micrograms/kg BID
Number of subjects: 23
Study 8923830 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I 30 micrograms/kg BID
Number of subjects: 23
Study 8923830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1615140 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg
Number of subjects: 0
Study 1615140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1615140 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 0
Study 6087368 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam/pivampicillin
Number of subjects: 139
Study 6087368 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 139
Study 30672832 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine (Iva, 7.5 mg b.i.d.)
Number of subjects: 23
Study 30592726 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm function parameters (thickness and range of motion)
Number of subjects: 142
Study 30592726 — intervention group
Group type: EXPERIMENTAL
Intervention: Limitation of diaphragm motion during quiet breathing and deep breathing
Number of subjects: 142
Study 30592726 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm muscle excursion during sniff maneuvers
Number of subjects: 142
Study 30592726 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration of diaphragm function after thoracic surgery
Number of subjects: 142
Study 30592726 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease of muscle thickness and movement restriction
Number of subjects: 142
Study 28683244 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS)
Number of subjects: 0
Study 24472122 — intervention group
Group type: EXPERIMENTAL
Intervention: High Five for Kids intervention
Number of subjects: 445
Study 24472122 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 445
Study 22253222 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional Help Sheet (VHS)
Number of subjects: 56
Study 22253222 — intervention group
Group type: COMPARATOR
Intervention: Active Control
Number of subjects: 56
Study 22253222 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 20167185 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Behavioral Therapy (TBT) sessions conducted thrice weekly for 12 weeks by phone, lasting an average of 15 minutes each.
Number of subjects: 32
Study 20167185 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 32
Study 20167185 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Behavioral Therapy (TBT) sessions.
Number of subjects: 32
Study 18055037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination fibrinolysis with 50 mg alteplase and tirofiban
Number of subjects: 151
Study 18055037 — intervention group
Group type: EXPERIMENTAL
Intervention: Upstream tirofiban
Number of subjects: 151
Study 18055037 — intervention group
Group type: COMPARATOR
Intervention: Control group (provisional abciximab)
Number of subjects: 151
Study 18055037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination fibrinolysis
Number of subjects: 151
Study 16368450 — intervention group
Group type: EXPERIMENTAL
Intervention: T40/H12.5
Number of subjects: 1402
Study 16368450 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/H12.5
Number of subjects: 1402
Study 16368450 — intervention group
Group type: COMPARATOR
Intervention: L50/H12.5
Number of subjects: 1402
Study 12449447 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy full-term infants
Number of subjects: 50
Study 12449447 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy preterm infants
Number of subjects: 50
Study 12449447 — intervention group
Group type: EXPERIMENTAL
Intervention: Diseased preterm infants
Number of subjects: 50
Study 12449447 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 50
Study 10323626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 42
Study 10323626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 8597321 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole, 200 mg/d for 2 weeks; then fluconazole, 200 mg/d and rifabutin, 300 mg/d for 2 weeks; then rifabutin, 300 mg/d for 2 weeks
Number of subjects: 12
Study 1912915 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (three extra lessons a week of an ordinary school physical education programme for eight months)
Number of subjects: 137
Study 7231652 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 0
Study 7231652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7231652 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 30141966 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleaner-burning biomass-fueled cookstove intervention (CAPS)
Number of subjects: 1481
Study 27712932 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine and clonidine (15 μg/ml)
Number of subjects: 200
Study 27712932 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine and adrenaline (12.5 μg/ml)
Number of subjects: 200
Study 26206217 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) promotion and encouragement from health care professionals, including physical therapists, individually or in groups.
Number of subjects: 18
Study 26206217 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized strategies to overcome challenges and barriers to PA.
Number of subjects: 18
Study 26206217 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal preferences and osteoporosis-related concerns influencing habitual PA.
Number of subjects: 18
Study 26206217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of PA promotion and conflicting advice from physicians.
Number of subjects: 18
Study 25812386 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet engine noise exposure
Number of subjects: 60
Study 25812386 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-noise exposed)
Number of subjects: 60
Study 21953475 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Trauma Fracture Liaison (MTFL) service
Number of subjects: 0
Study 21953475 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 20305868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit (3M ESPE)
Number of subjects: 100
Study 20305868 — intervention group
Group type: EXPERIMENTAL
Intervention: DuoTemp (Coltane/Whaledent)
Number of subjects: 100
Study 20305868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac (3M ESPE)
Number of subjects: 100
Study 20305868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination technique using Ketac and Cavit
Number of subjects: 100
Study 20305868 — intervention group
Group type: COMPARATOR
Intervention: All materials (Cavit, DuoTemp, Ketac)
Number of subjects: 100
Study 17608134 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxy methyl propyl cellulose based formulation
Number of subjects: 441
Study 17608134 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer based formulation
Number of subjects: 441
Study 17608134 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 441
Study 15703343 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric services (average of at least 2.1 hours a year)
Number of subjects: 604
Study 15703343 — intervention group
Group type: COMPARATOR
Intervention: Less than 2.1 hours a year of psychiatric services
Number of subjects: 604
Study 12193818 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein procedure
Number of subjects: 84
Study 12193818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nyhus procedure
Number of subjects: 84
Study 12193818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bassini procedure
Number of subjects: 84
Study 12193818 — intervention group
Group type: COMPARATOR
Intervention: TEP mesh hernioplasty
Number of subjects: 84
Study 9790154 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment (CT) with clonazepam for another 5 months
Number of subjects: 0
Study 9790154 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation treatment (DT) using a clonazepam taper at the rate of 0.25 mg every 2 weeks
Number of subjects: 0
Study 9790154 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation treatment (CT)
Number of subjects: 0
Study 9790154 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation treatment (DT)
Number of subjects: 0
Study 7815837 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission induction with 3 days daunorubicin and 7 days cytosine arabinoside
Number of subjects: 80
Study 7815837 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatment after initial induction
Number of subjects: 80
Study 7815837 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation treatment (standard maintenance, intensive consolidation courses, autologous or allogeneic transplantation)
Number of subjects: 80
Study 7815837 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-free survival for patients less than 45 years of age with M2 and M3 subtypes
Number of subjects: 80
Study 7815837 — intervention group
Group type: EXPERIMENTAL
Intervention: Projected survival for M3 patients
Number of subjects: 80
Study 7815837 — intervention group
Group type: COMPARATOR
Intervention: Death rate during remission induction
Number of subjects: 80
Study 2577568 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y + pouch
Number of subjects: 78
Study 2577568 — intervention group
Group type: EXPERIMENTAL
Intervention: Interposition + pouch
Number of subjects: 78
Study 2577568 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 78
Study 29566443 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice (MC)
Number of subjects: 10
Study 29566443 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 28351410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Rehabilitation (12 weekly group sessions of 90 min each)
Number of subjects: 0
Study 28351410 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 28351410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Rehabilitation
Number of subjects: 0
Study 26708885 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (dendritic cells and cytokine‐induced killer cells, DC‐CIK) combined with chemotherapy
Number of subjects: 36
Study 26708885 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (DC‐CIK) combined with chemotherapy
Number of subjects: 36
Study 26708885 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 36
Study 24083402 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox for up to 2 years
Number of subjects: 0
Study 24083402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21911192 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol and tropisetron (Group HT)
Number of subjects: 480
Study 21911192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimenhydrinate and dexamethasone (Group DD)
Number of subjects: 480
Study 21911192 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Group P)
Number of subjects: 480
Study 18413496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 0
Study 18413496 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride treatment
Number of subjects: 0
Study 18413496 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in HDL cholesterol
Number of subjects: 0
Study 16789988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2G 12 hourly
Number of subjects: 255
Study 16789988 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/Sulbactam 3 g 8 hourly and Aztreonam 2 g 8 hourly
Number of subjects: 255
Study 12832310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Therapy (IT)
Number of subjects: 142
Study 12832310 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 142
Study 11069815 — intervention group
Group type: EXPERIMENTAL
Intervention: TB‐FV loop analysis
Number of subjects: 113
Study 8842575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate infusion
Number of subjects: 0
Study 8842575 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lactate + Acetazolamide infusion
Number of subjects: 0
Study 8842575 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide alone
Number of subjects: 0
Study 1616890 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5FU), 13.5 mg/kg for five days (arm A)
Number of subjects: 181
Study 1616890 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose folinic acid (FA), 200 mg/m2 for five days and 5FU, 400 mg/m2 for five days (arm B)
Number of subjects: 181
Study 1616890 — intervention group
Group type: COMPARATOR
Intervention: 5FU alone (arm A)
Number of subjects: 181
Study 1616890 — intervention group
Group type: EXPERIMENTAL
Intervention: 5FU plus FA (arm B)
Number of subjects: 181
Study 6387968 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline (10 micrograms administered intravenously 5 minutes before amniocentesis)
Number of subjects: 19
Study 6387968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30682037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue vaccine with a true VE of 0.8
Number of subjects: 1000
Study 30682037 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue vaccine
Number of subjects: 1000
Study 29533864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular oxytocin administration within the first minute following the delivery of the fetus (10 IU)
Number of subjects: 343
Study 29533864 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin administration immediately following placental delivery (10 IU)
Number of subjects: 343
Study 26751193 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus hesperidin (500 g hesperidin with 500 mg calcium)
Number of subjects: 12
Study 26751193 — intervention group
Group type: COMPARATOR
Intervention: Hesperidin alone
Number of subjects: 12
Study 25248449 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation for 5 minutes
Number of subjects: 10
Study 25248449 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 10
Study 22775152 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 1% vaporized in closed eyes
Number of subjects: 50
Study 22775152 — intervention group
Group type: COMPARATOR
Intervention: Tropicamide 1% instilled in open eyes
Number of subjects: 50
Study 20098310 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqualase
Number of subjects: 75
Study 20098310 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification
Number of subjects: 75
Study 17963493 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Psychodynamic Supportive Psychotherapy
Number of subjects: 0
Study 17963493 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy
Number of subjects: 0
Study 15831773 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (201 mg/d)
Number of subjects: 12
Study 15831773 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily)
Number of subjects: 12
Study 15831773 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fenofibrate (201 mg/d) plus rosiglitazone (4 mg twice daily)
Number of subjects: 12
Study 15831773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12472326 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice improvement intervention
Number of subjects: 7920
Study 12472326 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 7920
Study 9473999 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable ultrasound device (PUD)
Number of subjects: 38
Study 9473999 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 8998248 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) 5 to 10 mg once daily
Number of subjects: 42
Study 8998248 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 to 25 mg once daily
Number of subjects: 42
Study 8998248 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (HCTZ + AML) after 8 weeks of monotherapy
Number of subjects: 42
Study 2115215 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 72
Study 2115215 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 72
Study 363217 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative metronidazole medication
Number of subjects: 30
Study 363217 — intervention group
Group type: COMPARATOR
Intervention: Preoperative mechanical bowel preparation and oral neomycin
Number of subjects: 30
Study 29600588 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month programmed sports therapy (PST)
Number of subjects: 50
Study 28241776 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT)
Number of subjects: 98
Study 28241776 — intervention group
Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 98
Study 25958079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Number of subjects: 441
Study 25958079 — intervention group
Group type: COMPARATOR
Intervention: Active Control (Sevelamer Carbonate and/or Calcium Acetate)
Number of subjects: 441
Study 23650950 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 600 mg HR, Thioctacid, three doses
Number of subjects: 78
Study 23650950 — intervention group
Group type: COMPARATOR
Intervention: Control group (hydration only)
Number of subjects: 78
Study 23650950 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 78
Study 23650950 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 21178591 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (CST)
Number of subjects: 171
Study 18808278 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving condition (participants abstained from eating chocolate for 24 hours prior to testing and performed cognitive tasks in the presence of chocolate)
Number of subjects: 0
Study 18808278 — intervention group
Group type: COMPARATOR
Intervention: Control condition (participants not specified, but presumably did not abstain from chocolate)
Number of subjects: 0
Study 16302600 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic appliances (experimental group)
Number of subjects: 64
Study 16302600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthodontic appliances)
Number of subjects: 64
Study 12077006 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually guided saccades in Parkinson's disease subjects
Number of subjects: 24
Study 12077006 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-guided saccades in Parkinson's disease subjects
Number of subjects: 24
Study 12077006 — intervention group
Group type: EXPERIMENTAL
Intervention: Centripetal adaptation in Parkinson's disease subjects
Number of subjects: 24
Study 12077006 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal adaptation in Parkinson's disease subjects
Number of subjects: 24
Study 12077006 — intervention group
Group type: COMPARATOR
Intervention: Visually guided saccades in controls
Number of subjects: 24